Complex genotype-phenotype relationships shape the response to treatment of down syndrome childhood acute lymphoblastic leukaemia
Extensive genetic and epigenetic variegation has been demonstrated in many malignancies. Importantly, their interplay has the potential to contribute to disease progression and treatment resistance. To shed light on the complex relationships between these different sources of intra-tumour heterogene...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
25 November 2025
|
| In: |
Scientific reports
Year: 2025, Volume: 15, Pages: 1-13 |
| ISSN: | 2045-2322 |
| DOI: | 10.1038/s41598-025-28779-9 |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1038/s41598-025-28779-9 Verlag, kostenfrei, Volltext: https://www.nature.com/articles/s41598-025-28779-9 
|
| Author Notes: | Christoph Lutz, Virginia A. Turati, Ruth Clifford, Petter S. Woll, Thomas Stiehl, Anders Castor, Sally A. Clark, Helen Ferry, Veronica Buckle, Andreas Trumpp, Anthony Ho, Anna Marciniak-Czochra, Javier Herrero, Anna Schuh, Sten Eirik W. Jacobsen, and Tariq Enver |
| Summary: | Extensive genetic and epigenetic variegation has been demonstrated in many malignancies. Importantly, their interplay has the potential to contribute to disease progression and treatment resistance. To shed light on the complex relationships between these different sources of intra-tumour heterogeneity, we explored their relative contributions to the evolutionary dynamics of Acute Lymphoblastic Leukaemia (ALL) in children with Down syndrome, which has particularly poor prognosis. We quantified the tumour propagating potential of genetically distinct sub-clones using serial transplantation assays and SNP-arrays. While most leukaemias were characterized by a single dominant subclone, others were highly heterogeneous. Importantly, we provide clear and direct evidence that genotypes and phenotypes with functional relevance to leukemic progression and treatment resistance can co-segregate within the disease. Hence, individual genetic lesions can be restricted to well-defined cell immunophenotypes, corresponding to different stages of the leukemic differentiation hierarchy and varied proliferation potentials. As a result of this difference in fitness, which can be accurately quantified via competitive transplantation assays, matching diagnostic, post-treatment, and relapse leukaemias can be dominated by different genotypes, including pre-leukemic clones persisting throughout the disease progression and treatment. Intriguingly, plasticity also appears to be a temporally defined property that can segregate with genotype. These results suggest that Down Syndrome ALL should be viewed as a complex matrix of cells exhibiting genetic and epigenetic heterogeneity that foster extensive clonal evolution and competition. Therapeutic intervention reshapes this ‘eco-system’ and may provide the right conditions for the preferential expansion of selected compartments and subsequently relapse. |
|---|---|
| Item Description: | Gesehen am 10.03.2026 |
| Physical Description: | Online Resource |
| ISSN: | 2045-2322 |
| DOI: | 10.1038/s41598-025-28779-9 |